PD87 Costs of Emicizumab in Hemophilia A: Comparison Between Post-Incorporation Expenses and Government Projections in Brazil
Juliana Alvares-Teodoro, Livia Nassif, Ricardo Mesquita Camelo, Augusto Guerra, Marina Silva, Luila Clicia, Barbara Santos, Francisco Acurcio · 2025
Read PD87 Costs of Emicizumab in Hemophilia A: Comparison Between Post-Incorporation Expenses and Government Projections in Brazil by Juliana Alvares-Teodoro, Livia Nassif, Ricardo Mesquita Camelo, Augusto Guerra, Marina Silva, Luila Clicia, Barbara Santos, Francisco Acurcio (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12768773.txt.
Description
Juliana Alvares-Teodoro and seven co-authors report a 2025 conference study on the cost of a hemophilia drug in Brazil. Hemophilia A leaves the blood short of a clotting factor, so patients bleed without warning. A newer drug, emicizumab, copies that factor's job and was added to the public health system in 2019 for patients whose bodies block the standard treatment.
The team tracked fifty-six patients with moderate to severe disease across sixteen treatment centers. They tallied what care cost in the year before the new drug and in the first year on it, using prices the health ministry actually paid. Those real costs were then set against what the government had forecast when it adopted the drug. The study gives planners a check on whether a costly new therapy fits the budget they planned for it.
Catalog record
| CREATOR | Juliana Alvares-Teodoro, Livia Nassif, Ricardo Mesquita Camelo, Augusto Guerra, Marina Silva, Luila Clicia, Barbara Santos, Francisco Acurcio |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |